Showing results (131-140 of 305) with videos related to

Sort By:
Pageof 31
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphomaMarco Ladetto, Michele Magni, Gloria Pagliano, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event resultsAntonio Palumbo, Patrizia Falco, Antonietta Falcone, et al.
Haematologica|July 13, 2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesSimona Caltagirone, Marina Ruggeri, Simona Aschero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 9, 2017
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple MyelomaLuisa Giaccone, Andrea Evangelista, Francesca Patriarca, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
Blood Cancer Journal|July 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Haematologica|January 8, 2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialAntonio Palumbo, Alessandra Larocca, Mariella Genuardi, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaBachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, et al.
Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.
Pageof 31